New pill targets tough cancers: first human trial begins
Disease control
Recruiting now
This early-stage study tests a new oral drug, KST-6051, in adults with advanced lung, pancreatic, colorectal, or other solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 145 participants who have not responded to standard trea…
Phase: PHASE1 • Sponsor: Kestrel Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:22 UTC